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Abstract
Background: The age gap between participants in trials and patients who could benefit from the drugs studied
has been widely documented across different clinical areas. Patients with dementia included in clinical research are
systematically younger than those in the general population. We examined the age gap between participants in
recent clinical trials testing interventions for Alzheimer’s disease and epidemiological data.
Methods: We systematically searched literature databases (MedLine, EMBASE, the Cochrane Library) and ClinicalTrials.
gov from 2000 to July 2015 to retrieve clinical trials testing pharmacologic treatments for Alzheimer’s disease, other
than cholinesterase inhibitors and memantine. We included ongoing and completed phase II/III randomized clinical
trials, irrespective of their publication status. From each study reporting the participants’ ages, we extracted size of
sample, mean age, and standard deviation, and estimated the proportions of participants in different age classes. The
number of patients with Alzheimer’s disease by age class in the USA population was used for comparison.
Results: We included 165 clinical trials testing almost 100 different compounds, which enrolled or planned to enroll
about 74,300 participants. Seventy-nine of these trials, accounting for about 26,800 participants, reported the age of the
participants. The weighted mean age was 73.6 years (standard deviation, 8.2). People younger than 80 years were
highly represented in clinical trials (78 %), despite the fact that those aged 80 and older form the majority (72 %) of
patients with Alzheimer’s disease. Only 8 % of clinical trial participants were 85 years or older.
Conclusions: Patients enrolled in clinical trials on Alzheimer’s disease are far from being representative of actual
distribution of the patients in the general population. Clinical research should not be designed and conducted
overlooking the fact that the majority of individuals with Alzheimer’s disease are likely to be 80 or older.
Keywords: Age, Alzheimer’s disease, Clinical trials, Disease-modifying drugs, External validity, Inclusion criteria, Trial
participants
Background
Between 1993 and 2003, four acetylcholinesterase inhibitors
and memantine were licensed in the USA and Europe for
the symptomatic treatment of Alzheimer’s disease [1, 2]. In
the last few decades, research has shifted mainly towards
putative disease-modifying agents. Although several candi-
date drugs have been tested in phase II and III trials, no
new treatments have been licensed since 2002 in Europe
and 2003 in the USA [3, 4]. Two reviews identified
about 200 drug development failures for Alzheimer’s
disease [5, 6].
Irrespective of the fact that these drugs did not reach
the market in the end, it is important to investigate
whether the participants enrolled in this large number of
trials were representative of the general population of
patients who would have received a drug if it had been
marketed. In the late 1990s, Schneider and co-authors
estimated the percentage of patients with Alzheimer’s
disease in a general clinical population who might have
been eligible for inclusion in two typical, industry-
sponsored trials testing the efficacy of symptomatic
drugs for Alzheimer’s disease [7]: only a small propor-
tion (4.4–7.9 %) of the overall clinical population of
Alzheimer’s disease patients would have been eligible for
each of the two trials. Women were under-represented
and the very few eligible patients were younger, better
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educated, and wealthier than the ineligible patients. This
was confirmed by a recent review on the representative-
ness of patients included in trials on acetylcholinesterase
inhibitors, which showed that participants were younger
than real-life patients with Alzheimer’s disease and women
were under-represented [8]. Given the large numbers of
trials on Alzheimer’s disease in the last few decades, it
seemed worth assessing the recent Alzheimer’s disease
agenda.
The age gap between participants in trials and patients
who could benefit from the study drugs has been widely
documented across different clinical areas [9, 10]. People
with dementia who are included in clinical research are
systematically younger than patients from the general
population: a review found a gap of about 8 years in the
mean age [11]. However, the prevalence of Alzheimer’s
disease and dementia increases considerably with age,
being fairly low among people aged under 75 and much
higher in the oldest groups [12, 13]. Considering the
census population projection, the total number of people
65 years and older with Alzheimer’s disease in the USA
is currently estimated at 5.1 million, 2.0 million of them
aged 85 and older (39 %) and 0.8 million aged 65–74
years (16 %). In 2050, the total number of persons 65
years and older with Alzheimer’s disease may reach 13.8
million, with 7.0 million 85 or older (51 %) and 1.3 million
65–74 years (9 %) [14].
Whether patients included in clinical trials are repre-
sentative of those who would be exposed to new drug
treatments in clinical practice is, therefore, a major
question. Patients in the general population may respond
differently to a drug than might those meeting the strin-
gent selection criteria of clinical trials, or may be exposed
to unexpected harm. Geriatric societies and regulatory
agencies have clearly stated that age should not be a bar-
rier to participation in trials and that participants should
reflect the population that will receive the drug once
marketed [15]. Concern about under-representation of
older participants is particularly relevant to conditions
like dementia and Alzheimer’s disease, which mainly
affect the oldest members of society.
This review examined whether the age of the partici-
pants in randomized clinical trials on Alzheimer’s dis-
ease reflects that of the people with the disease in the
general population. We focused on the recent Alzheimer’s
disease research agenda, i.e. pharmacological treatments
evaluated after the introduction of the symptomatic drugs
licensed in Europe and USA in the early 2000s, to add to
previous reviews [8, 11].
Methods
Criteria for considering studies for review
We followed a systematic approach to develop the sam-
ple for this study. We sought clinical trials that evaluated
one or more pharmacological interventions proposed to
improve cognitive or functional outcomes in participants
with a diagnosis of Alzheimer’s disease (any stage and
diagnostic criteria). We included ongoing and completed
phase II and III randomized clinical trials, irrespective
of their publication status. We excluded studies on
acetylcholinesterase and memantine because they had
already been analyzed and our review focused on the
most recent interventions for Alzheimer’s disease, aimed
at slowing the natural progression of the disease. We ex-
cluded studies testing non-pharmacological interventions
(e.g. herbal and natural products, dietary intervention, re-
habilitation, cognitive-behavioral approaches), diagnostic
tools (biomarkers), or interventions not addressing pa-
tients (e.g. caregivers). We also excluded phase I and I/II
studies assessing toxicity or optimal doses. Finally, we
excluded studies testing drugs to prevent the onset of
Alzheimer’s disease in subjects with no or mild cognitive
impairment.
Identification of studies
To identify eligible studies, we systematically searched
literature databases (MedLine, EMBASE, the Cochrane
Library) and the trial registry ClinicalTrials.gov from
2000 to July 2015. We also searched the proceedings
of the main international conferences in the field of
Alzheimer’s disease during the same period. Additional
file 1 reports details of search strategies.
Data collection and analysis
One review author screened the title and abstract to
assess eligibility. We considered this acceptable as the
inclusion criteria were simple, broad, and quite straight-
forward. Selection was inclusive at this stage and aimed
to exclude all records clearly irrelevant for the purpose
of this review. A random sample of the abstracts (15 %)
was then screened by a second reviewer to check the
accuracy of the process. Two authors independently
confirmed the eligibility and extracted the data using an
ad-hoc extraction form. For each study included, we ex-
tracted the year of publication or registration, trial name
and registration number; publication status (published,
terminated, ongoing, etc.); countries, sponsors and type
of funding (public or private); study design (cross-over,
parallel, blinded); number of patients (actually enrolled
or planned to be enrolled), inclusion and exclusion cri-
teria (type of diagnostic criteria, age and Mini-Mental
State Examination range at inclusion, stage of the disease,
main exclusion criteria, and prohibited concomitant medi-
cations); experimental and control interventions; main
mechanism of action; length of treatment and follow-up,
and the primary outcome measure. We also extracted
demographic variables, including age, sex, and years of
education. We did not assess possible biases affecting the
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internal validity of trials, as our aim was to evaluate the
representativeness of the population included, which af-
fects the external validity of the trial results.
From the subset of studies that reported the age of the
population included, we extracted the size of the popula-
tion, mean age, and standard deviation. When median
and quartiles were reported instead of mean and stand-
ard deviation, we calculate the mean from the average of
the 25, 50 and 75 percentiles (obtaining, as expected,
numbers very close to the reported medians); we calcu-
lated the standard deviation by multiplying the mean of
the differences between quartiles and estimated mean by
1.5. We calculated the mean of the standard deviations
of the studies included and assumed that this variability
also applied to the studies that did not give enough
details to calculate the standard deviation, e.g. those
reporting age as mean (or median) and range (min–max).
We considered it unfeasible to contact the authors or
principal investigators to collect missing information.
The proportion of subjects in the different age classes
was calculated assuming the age distribution was nor-
mal. We assumed a singly or doubly truncated normal
distribution for the studies that set a lower or upper age
limit, or both, in their inclusion criteria (e.g., patients up
to 85 years of age). For each study, we used the mean
and standard deviation to calculate the percentiles corre-
sponding to the specified age classes, then multiplied the
difference between these consecutive percentiles by the
size of the population to obtain an estimate of the num-
ber of patients in the specified age classes. Two studies
reported the mean and standard deviation and the distri-
bution in some age classes, which meant that we could
check the accuracy of this estimation: the concordance
was roughly 90 %, suggesting that estimations and actual
values were similar at least in the small sample available.
For each study, we then estimated the numbers of
participants in the following age classes: less than 65,
65–74, 75–84, and 85 years and older. We chose these
classes to permit direct comparison with the number of
Alzheimer’s disease patients in the US population [16].
Since the 10 year age class 75–84 comprises a particu-
larly heterogeneous population, we split it into two 5
year classes (75–79 and 80–84) to permit more detailed
comparison of the proportion of Alzheimer’s disease pa-
tients enrolled in clinical trials and in the general popu-
lation. We used data from the Aging, Demographics,
and Memory study ([17] and personal communication)
and the Framingham study [18] as sources of prevalence
data in these 5 year age classes.
Results
Database searches returned 3293 entries; 2982 were ex-
cluded by screening titles and abstracts and 311 were
assessed for eligibility. Of these, 115 were excluded mainly
because they were phase I or I/II trials, or phase II trials
without efficacy endpoints as primary outcome, or were
assessing vitamins, herbs or other natural products, or
preventive strategies (see Fig. 1 and Additional file 2). We
included the remaining 196 that reported information on
165 single clinical trials listed in Additional file 3. In all,
these trials enrolled or planned to enroll about 74,300
participants.
At the time of data extraction, half the studies (80 out
of 166) had published their results either in scientific
papers or in trial registries, 28 were ongoing, 52 were
terminated or ended but not published, and 4 were re-
ported as ‘unknown’ in ClinicalTrials.gov. We could not
retrieve further information on one additional study whose
methods and analysis plan were published in 2002 [19].
Two published their trial protocols in medical journals
[19, 20]. One-third were phase III trials.
We included trials on almost 100 different compounds,
the majority proposed as anti-amyloid therapies, modula-
tors of different neurotransmitter pathways (cholinergic,
histaminergic, serotoninergic, etc.), or tau-protein modula-
tors (Table 1). Several drugs were claimed to modify the
natural progression of the disease by interfering with the
pathogenic steps responsible for the clinical symptoms, in-
cluding, for example, the deposition of extracellular amyl-
oid beta plaques and intracellular neurofibrillary tangles,
inflammation, oxidative damage, glucose and cholesterol
metabolisms.
The majority of trials evaluated a population with mild
to moderate Alzheimer’s disease (132 of 165, 80 %), de-
fined as probable (127 of 165, 77 %) according to the
diagnostic criteria of the National Institute of Neurological
and Communicative Disorders and Stroke (NINCDS) and
the Alzheimer’s Disease and Related Disorders Association
(ADRDA) [21] (73 of 165 studies, 44 %) or to a combin-
ation of NINCDS-ADRDA and Diagnostic and Statis-
tical Manual of Mental Disorders criteria (28 of 165
studies, 17 %). Two-thirds were conducted in the USA,
Canada, and Europe and 23 % were global trials involving
clinical centers on at least three continents.
The eligibility criteria in terms of age varied. The lower
age limit was usually 50 years, though seven set it at 40
[22–25] or 45 years [26–28]. The upper limit was between
85 and 90 years in 42 % of studies. No upper age limit was
set in 44 % of the studies, meaning that, for example, any
participant older than 50 years could be enrolled.
Of the 165 studies, 79 provided data on the age of the
population enrolled, for a total of 26,845 participants
(Additional file 4). This subset of trials was used to cal-
culate the proportion of subjects in the different age
classes. The weighted mean age was 73.6 years (standard
deviation 8.2) while the estimated mean age of the
comparator population was 82 years [14]. Only 8 % of
participants in clinical trials were 85 years or older,
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while most were in the age classes 75–84 (35 %) and
65–74 (42 %). Excluding phase II trials did not substan-
tially change the proportion of patients in each class
(younger than 65, 15 %; 65–74, 41 %; 75–84, 36 %; 85
years or older, 9 %). These figures do not correspond to
the actual distribution of patients with Alzheimer’s disease
in the general population. In 2015, 81 % of people with
Alzheimer’s disease were 75 years or older and 38 % 85
years and older (Fig. 2) [16]. These proportions may well
reach 90 % and 51 % by 2050 [14].
The breakdown of the 75–84 age class showed that
the proportion of clinical trial participants 80–84 years
old accounted for more than one-third of the total (40 %
80–84 vs. 60 % 75–79, Fig. 3a). Alzheimer’s disease pa-
tients aged 80–84 years amount to three-quarters of
those in the general population (75 % 80–84 versus 25 %
75–79, Fig. 3a) [17, 18]. More generally, the proportion
of people 80 years and older reaches only about one-third
of participants in clinical trials, far fewer than the numbers
with Alzheimer’s disease of this age in the general
population (Fig. 3b).
Discussion
We analyzed recent trials of pharmacological treatments
for Alzheimer’s disease and found that the age of the
participants does not reflect the actual distribution of
patients in the general population. Individuals older than
84 years contribute greatly to the number of people with
Alzheimer’s disease (currently 38 %), a proportion that is
expected to grow further in the coming decades (to
about 51 % in 2050) [14]. Only 8 out of 100 trial partici-
pants in the sample fall into this class. In contrast, 15 %
of patients enrolled were younger than 65 years, so they
cannot even be defined as old. People younger than 80
are too widely represented in clinical trials, therefore,
despite the fact that those aged 80 and more are the
large majority with Alzheimer’s disease (72 %).
Involving old persons in clinical research is often
considered too challenging because coexisting diseases,
functional disability, and multi-drug treatments are
common and may confound trial results. Some authors
suggest that the differences between participants in ob-
servational and clinical studies and target population are
magnified when research involves older adults and that
this may reduce the generalizability [29]. Moreover,
ethical issues linked to the inclusion of a vulnerable
population have to be considered. However, any real or
alleged obstacle to research participation should be
weighed against the fact that excluding patients who
represent the largest part of the population with the
Fig. 1 Flow chart of studies in this review. AD, Alzheimer’s disease
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Table 1 Drugs tested in the clinical trials included in the review and mechanisms of actions
Class and proposed mechanism of action Drug Studies
Anti-amyloid
Reduced amyloid beta aggregation or oligomerization Tramiprosate (3APS) 3 phase III
Increased amyloid beta clearance, active immunotherapy AN1792 1 phase II
Sodium oligo-mannurarate 1 phase II, 1 phase III
Increased amyloid beta clearance, passive immunotherapy Solanezumab 3 phase III
Bapineuzumab 1 phase II, 4 phase III
Gantenerumab 2 phase III
BAN2401 1 phase II
Crenezumab 1 phase II
Aducanumab 2 phase III
Immunoglobulin 1 phase II, 3 phase III
Increased amyloid beta clearance, other Clioquinol (PBT-1) 1 phase II
Reduced amyloid beta production, gamma secretase inhibitor Semagacestat 2 phase II, 2 phase III
Reduced amyloid beta production, gamma secretase modulator Tarenflurbil 1 phase II, 2 phase III
Reduced amyloid beta production, beta secretase inhibitor MK-8931 1 phase II/III, 1 phase III
AZD3293 (LY3314814) 1 phase II/III
E2609 1 phase II
Glycation end products receptor (RAGE) inhibitors Azeliragon (TTP 488) 1 phase II, 1 phase III
Reduced amyloid beta Nilvadipine 1 phase III
Statins 1 phase II, 2 phase III
Anti-tau
Aggregation inhibitor TRx0237 (formerly TRx0014) 1 phase II, 2 phase III
Tideglusib 1 phase II
Modulators of blood glucose
Insulins 4 phase II, 1 phase II/III
Rosiglitazone 1 phase II, 3 phase III
Pioglitazone 2 phase II
AC 1204 2 phase II/III
Phosphodiesterase inhibitors
Phosphodiesterase 9A PF-04447943 1 phase II
BI 409306 2 phase II
Phosphodiesterase 5 Udenafil 1 phase III
Phosphodiesterase 4 MK 0952 1 phase II
Histamine modulators
GSK239512 1 phase II
MK0249 1 phase II
ABT 288 1 phase II
Nizatidine 1 phase ?
SAR110894D 1 phase II
S38093 2 phase II
Nicotine modulators
Nicotinic acetylcholine receptor partial agonist ABT-089 2 phase II
RO5313534 1 phase II
EVP-6124 1 phase II, 2 phase III
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Table 1 Drugs tested in the clinical trials included in the review and mechanisms of actions (Continued)
Varenicline 1 phase II
AZD3480 2 phase II
AQW051 1 phase II
α-7 nicotinic acetylcholine receptor allosteric modulator ABT-126 3 phase II
Muscarine modulators
Allosteric modulator MK 7622 1 phase II
Allosteric modulator Lu25-109 1 study ?
Non-selective muscarinic acetylcholine receptor agonist Talsaclidine 2 phase II
Serotonin modulators
5-hydroxytryptamine 6 receptor antagonist SB 742457 4 phase II
Lu AE58054 1 phase II, 2 phase III
SAM-531 1 phase II
5-hydroxytryptamine 1A receptor agonist Xaliproden 2 phase III
Palirodena 1 phase II
5-hydroxytryptamine 1 receptor antagonist Lecozotan 1 phase II, 1 phase II/III
5-hydroxytryptamine 4 receptor agonist PRX-03140 2 phase II
Other central nervous system transmitter modulators
Benzodiazepine receptor partial inverse agonist AC-3933 1 phase II
Norepinephrine uptake inhibitor Atomoxetine 1 phase II/III
NMDA receptor channel blocker Neramexane 1 phase III
Monoamine uptake inhibitor NS 2330 1 phase II
Adrenergic receptor antagonist ORM-12741 1 phase II
Irreversible monoamine oxidase inhibitor Rasagiline 1 phase II
GABA(B) receptor antagonist SGS742 1 phase II
Glutamate receptor modulator LY451395 1 phase II
Anti-inflammatory
Non-steroidal anti-inflammatory drugs Aspirin 1 phase III
Indomethacin 1 phase III
Ibuprofen 1 phase ?
Nimesulide 1 phase II
Rofecoxib 1 phase II/III, 1 phase ?
Celecoxib 1 phase III
Lornoxicam 1 phase II
Unknown mechanism Hydroxychloroquine 1 phase III
Astrocyte activator ONO-2506PO 1 phase II
PYM50028 1 phase II
Hormones and analogs
Antiprogestinic Mifepristone 3 phase II
Corticosteroid Prednisone 1 phase III
11-β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 1 phase II
Gonadotropin-releasing hormone analog Leuprolide acetate 1 phase II
Estrogen receptor modulator Raloxifene 1 phase II
HRT 5 phase ?
Androgen receptor modulator Dehydroepiandrosterone/testosterone 2 phase ?
Growth hormone secretagogue MK0677 1 phase II
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disease may lead to misinterpretation in the conclusions
about the underlying neuropathology, diagnostic methods,
or therapy [11].
In the case of Alzheimer’s disease and other conditions
that overwhelmingly affect old people, the inclusion of
representative samples of patients in trials testing in-
novative pharmacological approaches and new drugs
should be the rule. Older people have different pharma-
cokinetics and pharmacodynamics from people in their
60s or 70s [30]. These diversities may translate into differ-
ent efficacy and safety profiles; benefits as well as harms
may be under- or overestimated, depending on the disease
expression, and must be assessed before new drugs are
used. The results of robust and valid trials (internal valid-
ity) are also only clinically useful if they are relevant to a
definable patient population that should represent the tar-
get group of patients for the intervention under study.
This concept, known as external validity, applicability, or
generalizability, is often neglected, especially in industry-
sponsored research [10], which selects the best possible
experimental conditions to highlight the efficacy of new
treatments, often disregarding their effectiveness in the
real world.
Trial participants should reflect the actual distribution
of individuals with Alzheimer’s disease in terms of other
important aspects too, such as co-morbidities, cultural
and educational background, and frailty. These variables
may threaten the external validity of clinical trials in
Alzheimer’s disease as well as age.
In clinical practice too, subjects treated with the
marketed drugs are a small proportion of those with
Alzheimer’s disease. For instance, the largest propor-
tions of patients treated with acetylcholinesterase in-
hibitors were in the younger age groups, with a steep
drop with age: from 55 % at 60–69 years to 19 % at
80–84 years [31]. This may be because of perceived
low effectiveness of these drugs by both the caregiver
and the physician, difficulties with diagnoses of dementia,
significant concurrent pathologic abnormalities, adverse
drug reactions, or even a fatalistic acceptance of the condi-
tion. It is unlikely, however, that the reasons behind these
therapeutic decisions are linked to strict application of evi-
dence generated in a younger population.
Our analysis has several advantages. It focuses on the
most recent research on Alzheimer’s disease and adds to
previous reviews of trials of older interventions [8, 11].
We retrieved published and unpublished trials on putative
disease-modifying agents for Alzheimer’s disease using a
systematic approach and based our analysis on a large
sample of studies, covering different pharmacological
treatments, mechanisms of action, trial sponsors, and
countries. The sample can be considered highly repre-
sentative of current research in the field of Alzheimer’s
disease, even if we could not retrieve reports of about
one-third of the studies included. While it is uncertain
whether the inclusion of these trials would have changed
our findings, it is worrying that so many trial reports are
still inaccessible.
Table 1 Drugs tested in the clinical trials included in the review and mechanisms of actions (Continued)
Other or several mechanisms
c-kit (tyrosine kinase) inhibitor Masitinib 1 phase II, 1 phase III
Dimebon 2 phase II, 5 phase III
IFNβ-alpha 2a 1 phase II
IFNβ1a 1 phase II
N-acetylcysteine 1 phase II
Acetyl-L-carnitine 1 phase ?
Calcium antagonist MEM 1003 1 phase II
Pleiotropic ST101 2 phase II
Doxycycline and rifampin 1 phase II, 1 phase III
Cerebrolysin 4 phase II, 1 phase III
Somatostatin production enhancer FK962 1 phase II
Unknown VI-1121 1 phase II
Idebenone 1 phase ?, 1 phase III
Sodium oligo-mannurate 1 phase II
RO4601522 1 phase II
T-817MA 1 phase II
amechanism not fully elucidated
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Fig. 2 Distribution by age. Data from clinical trials and the estimated number of patients with Alzheimer’s disease in the USA in 2015 (source of
prevalence data: [16]). AD, Alzheimer’s disease
Fig. 3 a Distribution in the 75–79 and 80–84 age classes. Data from clinical trials and the estimated number of patients with Alzheimer’s disease
in the USA (source of prevalence data: [17, 18]). b Age distribution below and above age 80 years. Comparison of data from clinical trials and the
estimated number of patients with Alzheimer’s disease in the USA (source of prevalence data: [17, 18]). AD, Alzheimer’s disease
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One further limitation is the lack of reporting on the
proportions of patients per age class in clinical trials.
The age of the study population is generally described
using mean and standard deviation or median and range.
Thus, we could only estimate the proportion of patients
in each age class assuming a specific underlying distri-
bution, i.e., taking a normal distribution for reference.
This approximation, however, is likely to have had only
a limited impact on the overall conclusion of the re-
view, given the very large age differences between trial
participants and patients in the general population. To
understand the applicability of the evidence from clin-
ical trials to oldest people better, complete reporting of
the age distribution of the patients is a major, necessary
step forward.
Several studies reported prevalence data on dementia
[32], while a few focused specifically on Alzheimer’s dis-
ease. To estimate the number of people with Alzheimer’s
disease by age class in the general population, we used
prevalence data from different sources. This is because the
most recent figures we found indicated only the number
of people with Alzheimer’s disease by 10 year classes of
age [14]. Thus, to retrieve Alzheimer’s disease prevalence
estimates by 5 year classes, we referred to published and
unpublished data from previous cohort studies [17, 18].
Finally, we compared the ages of participants in clinical
trials only with the number of people with Alzheimer’s
disease in the USA because more than half the trials in-
volved clinical centers in North America. Comparison
with data from other population studies could be of inter-
est. However, our estimates are likely to be conservative as
taking as reference the populations of European countries,
Australia, Canada, and Japan, where the proportions of
older subjects (older than 65) and oldest subjects (older
than 80 or 85) are even larger than in the USA, would
have led to a more dramatic difference.
Conclusions
Lack of generalizability is an important obstacle to cor-
rect evidence-based practice. Taking USA data for com-
parison, the over-representation of younger old people
(below 80 years) in clinical trials is clear. Clinical trials
are the most reliable method of determining the effects
of treatments, and meeting the diverse needs of patients,
prescribers, regulators, and payers. They should collect
data on clinically meaningful outcomes measured in
populations representing the patients for whom the drug
will eventually be licensed. It is to be hoped that new ef-
fective drugs will be available in the near future to treat
Alzheimer’s disease, which is not only a devastating dis-
order, but also has a major social and economic impact
[33]. Clinical research should not be designed and con-
ducted so that it ignores the vast majority of Alzheimer’s
disease patients aged 80 or 85 years and older [13, 14].
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